文献速递妇科肿瘤

正常风险卵巢筛查研究:21年更新

Normal Risk Ovarian Screening Study: 21-Year Update.
PubMed 文献 · J Clin Oncol · 2024-01-09

NROSS单臂研究对7,856名健康绝经后女性每年行ROCA联合TVS两阶段筛查,共50,596人年。34例转诊手术检出15例卵巢癌和2例交界性肿瘤,其中12例为早期(I-II期);另检出7例子宫内膜癌,6例为I期。筛查使晚期(III-IV期)疾病较UKCTOCS对照降低34%,较美国SEER值降低30%。

要点

  • ROCA联合TVS筛查的卵巢癌和交界性肿瘤敏感性为74%(17/23),ROCA检出病例中70%(12/17)为I-II期。
  • 筛查使晚期(III-IV期)疾病较UKCTOCS对照降低34%,较美国SEER值降低30%。
  • 卵巢癌检出阳性预测值为50%(17/34),任何癌症为74%(25/34),远超研究预设最低可接受终点10%。

核心结论

  • NROSS试验未以检出死亡率降低为效能目标,但高特异性、阳性预测值和显著分期迁移支持进一步开发该筛查策略。

研究设计与样本

  • 单臂研究(ClinicalTrials.gov标识NCT00539162),纳入7,856名健康绝经后女性,每年筛查,共50,596人年。
  • 采用两阶段筛查策略:每年以卵巢癌风险算法(ROCA)分析血清CA125,风险升高者行经阴道超声(TVS),TVS异常者行手术。

主要发现

  • 34例患者转诊手术,检出15例卵巢癌和2例交界性肿瘤,其中12例为早期(I-II期)。
  • 另检出7例子宫内膜癌,其中6例为I期。
  • 4例卵巢癌和2例交界性肿瘤在ROCA正常时诊断,卵巢癌和交界性肿瘤检出敏感性为74%(17/23),ROCA检出病例中70%(12/17)为I-II期。
  • NROSS筛查使晚期(III-IV期)疾病较UKCTOCS对照降低34%,较美国SEER值降低30%。
  • 卵巢癌检出阳性预测值为50%(17/34),任何癌症为74%(25/34),远超研究最低可接受终点10%阳性预测值。

关键数值与推荐

  • ROCA风险不变且<1:2,000者一年后复查;风险升高>1:500者立即行TVS;风险居中者3个月后重复CA125,风险进一步升高>1:500者转诊TVS。
  • 每年平均2%的参与者转诊行TVS。
  • 卵巢癌和交界性肿瘤检出敏感性74%(17/23);ROCA检出病例中I-II期占70%(12/17)。
  • 卵巢癌检出阳性预测值50%(17/34),任何癌症阳性预测值74%(25/34);研究最低可接受终点为10%阳性预测值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • NROSS试验未以检出死亡率降低为效能目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Normal Risk Ovarian Screening Study (NROSS) tested a two-stage screening strategy in postmenopausal women at conventional hereditary risk where significantly rising cancer antigen (CA)-125 prompted transvaginal sonography (TVS) and abnormal TVS prompted surgery to detect ovarian cancer. METHODS: A total of 7,856 healthy postmenopausal women were screened annually for a total of 50,596 woman-years in a single-arm study (ClinicalTrials.gov identifier: NCT00539162). Serum CA125 was analyzed with the Risk of Ovarian Cancer Algorithm (ROCA) each year. If risk was unchanged and <1:2,000, women returned in a year. If risk increased above 1:500, TVS was undertaken immediately, and if risk was intermediate, CA125 was repeated in 3 months with a further increase in risk above 1:500 prompting referral for TVS. An average of 2% of participants were referred to TVS annually. RESULTS: Thirty-four patients were referred for operations detecting 15 ovarian cancers and two borderline tumors with 12 in early stage (I-II). In addition, seven endometrial cancers were detected with six in stage I. As four ovarian cancers and two borderline tumors were diagnosed with a normal ROCA, the sensitivity for detecting ovarian and borderline cancer was 74% (17 of 23), and 70% of ROCA-detected cases (12 of 17) were in stage I-II. NROSS screening reduced late-stage (III-IV) disease by 34% compared with UKCTOCS controls and by 30% compared with US SEER values. The positive predictive value (PPV) was 50% (17 of 34) for detecting ovarian cancer and 74% (25 of 34) for any cancer, far exceeding the minimum acceptable study end point of 10% PPV. CONCLUSION: While the NROSS trial was not powered to detect reduced mortality, the high specificity, PPV, and marked stage shift support further development of this strategy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Han CY, Lu KH, Corrigan G, et al. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol. 2024. PMID: 38194613. doi:10.1200/JCO.23.00141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。